Study of Cisplatin-Induced Peripheral Neuropathy in Patients with Germ Cell Tumor


About this study

The purpose of this study is to investigate the incidence, characteristics of, and changes in chronic neuropathy symptoms related to cisplatin and evaluate the natural history of platinum induced peripheral neuropathy during active treatment and the first 12 months post chemotherapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • 15 years of age or older at the time of informed consent
  • Has a confirmed pathologic and/or by tumor marker diagnosis of testicular or extragonadal germ cell cancer
  • Provide written informed consent and assent (if applicable)
  • Ability to complete questionnaire(s) in English by themselves or with assistance
  • Willing to provide a 10 mL blood sample for future DNA testing
  • Planning to receive at least 3 cycles of cisplatin (20 mg/m2/d for 5 days) based chemotherapy
  • Must agree to continued clinical follow-up at the study cancer center

Exclusion Criteria

  • Diagnosis (current or previous) of peripheral neuropathy (from diabetes or other causes)
  • Previous exposure to neurotoxic chemotherapy drugs including taxanes, platinum agents, vinca alkaloids, or epothilones
  • Salvage chemotherapy treatment or bone marrow transplant
    • Salvage chemotherapy is defined as any treatment after relapse of the disease following initial chemotherapy treatment

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brian Costello, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information


Publications are currently not available

Mayo Clinic Footer